Another Major Drug Approval for Regeneron
Congratulations to BCW member Regeneron on the approval of an important new drug to help patients with rheumatoid arthritis. The U.S. Food and Drug Administration has approved the human antibody drug sarilumab, developed by Regeneron Pharmaceuticals Inc. in Westchester and its French pharmaceutical partner Sanofi and trademarked as Kevzara, to treat adult patients with moderately to severely active rheumatoid arthritis.
The FDA approval came less than two months after the federal agency approved Regeneron’s and Sanofi’s human antibody dupilumab, marketed as Dupixent, as the first biologic medicine used to treat the debilitating itching and widespread rashes afflicting adults with moderate to severe cases of atopic dermatitis.
Similar News Items
BCW Member Extell Development Company joined with Yonkers Mayor Mike Spano and other city, county and state officials for a ribbon-cutting ceremony for Hudson Piers on Wednesday, signifying the official grand opening of the new luxury, multi-phase development. Additionally, Hudson Piers signifies the final and largest piece of the Downtown Waterfront Revitalization in Yonkers which […]
Westchester County’s healthcare landscape is undergoing a profound transformation, according to panelists at the Business Council of Westchester’s State of the Economy series held this week. The insightful panel discussion on Tuesday delved into several key trends reshaping medical care in the region. The distinguished panelists included Dan Blum, Chief Executive Officer, ENT & Allergy; […]
As Westchester County’s largest business membership organization focused on economic development and advocacy, the BCW has been a consistent proponent of ensuring that childcare is a priority on all levels of government. BCW has also hosted numerous business roundtable discussions to address this critical issue. According to the NYS Department of Labor’s Child Care Report, […]
Become A Member
Join the county’s largest and most influential business organization today.
JOIN NOW!
Leave a Comment
You must be logged in to post a comment.